ClinicalTrials.gg
Active, not recruitingNCT06267365Updated Nov 17, 2026

Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis

An observational study in Chronic Pancreatitis, sponsored by NYU Langone Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by NYU Langone Health · Observational

How we know

Updated Nov 17, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 111 studies in Pancreatitis, Chronic with a site in United States — 27 open to participants now, 38 under way, none of them phase 3. Pancreatitis, Chronic · United States.

Enrollment
36th of 38
25 · median 167
Started
2023
with 4 others
Observational
38 of 111
10 open now
Primary completion
2027-05
later than 13 of 37 live
Registered
92nd of 111
by date

Among the 111 studies in Pancreatitis, Chronic with a site in United States, this one is the 36th largest by enrollment of the 38 observational ones that give a count, is one of 5 that started in 2023, is one of 38 observational ones, reaches primary completion later than 13 of the 37 other live ones, and was the 92nd registered.

Pancreatitis, Chronic

266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.

Browse Pancreatitis, Chronic studies →

Open to participants now

27 of the 111 studies in Pancreatitis, Chronic with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Pancreatitis, Chronic with a site in United States, or all of them as a file.
02

Study summary

This is an observational prospective study to develop predictive biomarkers for pain response in participants with chronic pancreatitis scheduled for endoscopic therapy. Participants will undergo baseline assessments including electroencephalography (EEG), quantitative sensory testing (QST), and psychosocial questionnaires. Response to endoscopic therapy will be assessed at approximately 3, 6, 12 and 18 months post-procedure using questionnaires.

03

Conditions studied

  • Chronic Pancreatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults older than 18 years with painful chronic pancreatitis scheduled for endoscopic therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adults older than 18 years;
  • Cambridge III or IV criteria for Chronic Pancreatitis (CP); or M-ANNHEIM criteria for definitive chronic pancreatitis;
  • scheduled for endoscopic therapy for ductal obstruction (may include lithotripsy, pancreatic duct dilation, or stone extraction to facilitate successful stenting) as part of routine clinical care based on multidisciplinary review;
  • pain present for ≥ 3 days per week for ≥ 3 months;
  • average pain over the last week ≥ 4 on a 11-point numeric rating scale (NRS).

Exclusion criteria

Exclusion Criteria:

  • chronic pain syndrome other than CP;
  • episode of acute pancreatitis within 2 months of enrollment;
  • endoscopic therapy including Endoscopic retrograde cholangiopancreatography (ERCP), Endoscopic ultrasound (EUS) Guided Celiac Plexus Block or pancreatic surgery \< 6 months prior to enrollment;
  • active illicit drug use (excludes marijuana use);
  • classification > 3;
  • immune-mediated pancreatitis or associated pancreatic neoplasms
  • Major neurological disease such as stroke, uncontrolled epilepsy, dementia
  • Diagnosis of schizophrenia
  • Chronic benzodiazepine use. Use of short acting benzodiazepine on as needed basis is acceptable if participant is able to hold benzodiazepine prior to EEG recording.
  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Adult Patients with Painful Chronic Pancreatitis

    Participants with chronic pancreatitis scheduled for endoscopic therapy will undergo baseline assessments including EEG, quantitative sensory testing, and psychosocial questionnaires. Follow-up questionnaires will be completed at approximately 3, 6, 12 and 18 months post-procedure.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Brief Pain Inventory (BPI) Score at Month 3 Post-Operation

    BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.

    Time frame: Baseline, Month 3 Post-Operation

Secondary outcomes

  1. Change from Baseline in BPI Score at Month 6 Post-Operation

    BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.

    Time frame: Baseline, Month 6 Post-Operation

  2. Change from Baseline in BPI Score at Month 12 Post-Operation

    BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.

    Time frame: Baseline, Month 12 Post-Operation

  3. Change from Baseline in BPI Score at Month 18 Post-Operation

    BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain.

    Time frame: Baseline, Month 18 Post-Operation

  4. Change from Baseline in Patient Reported Outcome System (PROMIS) - Physical Function - Short Form 6b Score at Month 3 Post-Operation

    The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.

    Time frame: Baseline, Month 3 Post-Operation

  5. Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 6 Post-Operation

    The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.

    Time frame: Baseline, Month 6 Post-Operation

  6. Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 12 Post-Operation

    The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.

    Time frame: Baseline, Month 12 Post-Operation

  7. Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 18 Post-Operation

    The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function.

    Time frame: Baseline, Month 18 Post-Operation

  8. Number of Participants who use Opioids at Baseline

    Time frame: Baseline

  9. Number of Participants who use Opioids at Month 3

    Time frame: Month 3

  10. Number of Participants who use Opioids at Month 6

    Time frame: Month 6

  11. Number of Participants who use Opioids at Month 12

    Time frame: Month 12

  12. Number of Participants who use Opioids at Month 18

    Time frame: Month 18

  13. Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 3 Post-Procedure

    The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.

    Time frame: Baseline, Month 3 Post-Procedure

  14. Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 6 Post-Procedure

    The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.

    Time frame: Baseline, Month 6 Post-Procedure

  15. Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 12 Post-Procedure

    The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.

    Time frame: Baseline, Month 12 Post-Procedure

  16. Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 18 Post-Procedure

    The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms.

    Time frame: Baseline, Month 18 Post-Procedure

  17. Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 3 Post-Procedure

    The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.

    Time frame: Baseline, Month 3 Post-Procedure

  18. Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 6 Post-Procedure

    The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.

    Time frame: Baseline, Month 6 Post-Procedure

  19. Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 12 Post-Procedure

    The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.

    Time frame: Baseline, Month 12 Post-Procedure

  20. Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 18 Post-Procedure

    The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety.

    Time frame: Baseline, Month 18 Post-Procedure

  21. Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 3 Post-Procedure

    The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.

    Time frame: Baseline, Month 3 Post-Procedure

  22. Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 6 Post-Procedure

    The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.

    Time frame: Baseline, Month 6 Post-Procedure

  23. Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 12 Post-Procedure

    The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.

    Time frame: Baseline, Month 12 Post-Procedure

  24. Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 18 Post-Procedure

    The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain.

    Time frame: Baseline, Month 18 Post-Procedure

  25. Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 3 Post-Procedure

    The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.

    Time frame: Baseline, Month 3 Post-Procedure

  26. Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 6 Post-Procedure

    The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.

    Time frame: Baseline, Month 6 Post-Procedure

  27. Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 12 Post-Procedure

    The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.

    Time frame: Baseline, Month 12 Post-Procedure

  28. Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 18 Post-Procedure

    The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance.

    Time frame: Baseline, Month 18 Post-Procedure

  29. Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 3 Post-Procedure

    The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.

    Time frame: Baseline, Month 3 Post-Procedure

  30. Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 6 Post-Procedure

    The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.

    Time frame: Baseline, Month 6 Post-Procedure

  31. Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 12 Post-Procedure

    The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.

    Time frame: Baseline, Month 12 Post-Procedure

  32. Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 18 Post-Procedure

    The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue.

    Time frame: Baseline, Month 18 Post-Procedure

  33. Change from Baseline in Pain Catastrophizing Scale (PCS) Score at Month 3 Post-Procedure

    The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.

    Time frame: Baseline, Month 3 Post-Procedure

  34. Change from Baseline in PCS Score at Month 6 Post-Procedure

    The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.

    Time frame: Baseline, Month 6 Post-Procedure

  35. Change from Baseline in PCS Score at Month 12 Post-Procedure

    The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.

    Time frame: Baseline, Month 12 Post-Procedure

  36. Change from Baseline in PCS Score at Month 18 Post-Procedure

    The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing.

    Time frame: Baseline, Month 18 Post-Procedure

  37. Change from Baseline in Sleep Duration at Month 3 Post-Procedure

    Time frame: Baseline, Month 3 Post-Procedure

  38. Change from Baseline in Sleep Duration at Month 6 Post-Procedure

    Time frame: Baseline, Month 6 Post-Procedure

  39. Change from Baseline in Sleep Duration at Month 12 Post-Procedure

    Time frame: Baseline, Month 12 Post-Procedure

  40. Change from Baseline in Sleep Duration at Month 18 Post-Procedure

    Time frame: Baseline, Month 18 Post-Procedure

  41. Change from Baseline in Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Score at Month 3 Post-Procedure

    TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.

    Time frame: Baseline, Month 3 Post-Procedure

  42. Change from Baseline in TAPS Score at Month 6 Post-Procedure

    TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.

    Time frame: Baseline, Month 6 Post-Procedure

  43. Change from Baseline in TAPS Score at Month 12 Post-Procedure

    TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.

    Time frame: Baseline, Month 12 Post-Procedure

  44. Change from Baseline in TAPS Score at Month 18 Post-Procedure

    TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use.

    Time frame: Baseline, Month 18 Post-Procedure

  45. Change from Baseline in Patient Global Impression of Change (PGIC) Score at Month 3 Post-Procedure

    PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.

    Time frame: Baseline, Month 3 Post-Procedure

  46. Change from Baseline in PGIC Score at Month 6 Post-Procedure

    PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.

    Time frame: Baseline, Month 6 Post-Procedure

  47. Change from Baseline in PGIC Score at Month 12 Post-Procedure

    PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.

    Time frame: Baseline, Month 12 Post-Procedure

  48. Change from Baseline in PGIC Score at Month 18 Post-Procedure

    PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change.

    Time frame: Baseline, Month 18 Post-Procedure

  49. Change from Baseline in Patient Health Questionnaire-2 (PHQ-2) Score at Month 3 Post-Procedure

    PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.

    Time frame: Baseline, Month 3 Post-Procedure

  50. Change from Baseline in PHQ-2 Score at Month 6 Post-Procedure

    PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.

    Time frame: Baseline, Month 6 Post-Procedure

  51. Change from Baseline in PHQ-2 Score at Month 12 Post-Procedure

    PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.

    Time frame: Baseline, Month 12 Post-Procedure

  52. Change from Baseline in PHQ-2 Score at Month 18 Post-Procedure

    PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health.

    Time frame: Baseline, Month 18 Post-Procedure

  53. Change from Baseline in Generalized Anxiety Disorder 2 (GAD-2) Score at Month 3 Post-Procedure

    GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.

    Time frame: Baseline, Month 3 Post-Procedure

  54. Change from Baseline in GAD-2 Score at Month 6 Post-Procedure

    GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.

    Time frame: Baseline, Month 6 Post-Procedure

  55. Change from Baseline in GAD-2 Score at Month 12 Post-Procedure

    GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.

    Time frame: Baseline, Month 12 Post-Procedure

  56. Change from Baseline in GAD-2 Score at Month 18 Post-Procedure

    GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety.

    Time frame: Baseline, Month 18 Post-Procedure

  57. Change from Baseline in Pain, Enjoyment of Life and General Activity (PEG) Scale at Month 3 Post-Procedure

    PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.

    Time frame: Baseline, Month 3 Post-Procedure

  58. Change from Baseline in PEG Scale at Month 6 Post-Procedure

    PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.

    Time frame: Baseline, Month 6 Post-Procedure

  59. Change from Baseline in PEG Scale at Month 12 Post-Procedure

    PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.

    Time frame: Baseline, Month 12 Post-Procedure

  60. Change from Baseline in PEG Scale at Month 18 Post-Procedure

    PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference.

    Time frame: Baseline, Month 18 Post-Procedure

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — As an NIH-HEAL initiative sponsored study, our IPD sharing comply with the Helping to End Addiction Long-term (HEAL) Public Access and Data Sharing Policy. The de-identified participant data will be shared and deposited into the National Institute of Mental Health Data Archive (NIMH) Data Archive (NDA). The NDA provides metadata, study digital object identifier (DOI), and long-term access. This repository is supported by several institutes and centers at the NIH, and datasets are available through a request process. Investigators requesting data must be affiliated with an NIH-recognized research institution that maintains an active Federalwide Assurance (FWA), and complete and submit a Data Use Certification approved by an authorized institutional business official with signature authority. This request will then be reviewed by the NDA Data Access Committee.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Lisa.Doan@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for May 2027, 41 months after the start.

Of 57 non-industry observational studies under Pancreatitis, Chronic, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 160. This study's planned 41 months is below that.

Counting every sponsor, half of 59 studies reached it within 63 months; a quarter within 28 and three quarters within 160.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Mar 2027 → May 2027 and completion Jun 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Feb 20, 2024
StartActual
Nov 27, 2023
Primary completionEst.
May 1, 2027was Mar 2027
CompletionEst.
Dec 1, 2028was Jun 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Primary completion
Mar 1, 2027→May 1, 2027
Nov 17, 2026
Study completion
Jun 1, 2028→Dec 1, 2028
Nov 17, 2026
Enrollment
100 (estimated)→25 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 1, 2027→May 1, 2027
    Study completion Jun 1, 2028→Dec 1, 2028
    Enrollment 100 (estimated)→25 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06267365
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Nov 27, 2023
Primary completion
May 1, 2027 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Tamas Gonda, MD
principal investigator · NYU Langone Health
Lisa Doan, MD
principal investigator · NYU Langone Health
Jing Wang, MD, PhD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion